Sharon Cantor, PhD, has received an R01 grant from the National Cancer Institute to explore the role of BRCA1 in coordinating lagging strand DNA synthesis, with implications for developing new treatments for hereditary breast and ovarian cancers, including tumors resistant to PARP inhibitors.

Scot Wolfe, PhD, is developing a CRISPR-Cas9 strategy to selectively destroy cancer cells driven by focal gene amplification.